RVMD Revolution Medicines Inc

Price (delayed)

$17.78

Market cap

$1.32B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.82

Enterprise value

$1.29B

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities ...

Highlights
The debt has soared by 106% YoY
Revolution Medicines's net income has plunged by 65% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of RVMD
Market
Shares outstanding
74.25M
Market cap
$1.32B
Enterprise value
$1.29B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.39
Price to sales (P/S)
49.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.94
Earnings
Revenue
$26.84M
EBIT
-$207.56M
EBITDA
-$199.62M
Free cash flow
-$169.93M
Per share
EPS
-$2.82
Free cash flow per share
-$2.29
Book value per share
$7.43
Revenue per share
$0.36
TBVPS
$8.21
Balance sheet
Total assets
$682.77M
Total liabilities
$131.78M
Debt
$65.91M
Equity
$550.99M
Working capital
$476.89M
Liquidity
Debt to equity
0.12
Current ratio
9.3
Quick ratio
9.15
Net debt/EBITDA
0.17
Margins
EBITDA margin
-743.8%
Gross margin
100%
Net margin
-773.4%
Operating margin
-777.1%
Efficiency
Return on assets
-28.3%
Return on equity
-33.5%
Return on invested capital
-40%
Return on capital employed
-33.2%
Return on sales
-773.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RVMD stock price

How has the Revolution Medicines stock price performed over time
Intraday
1.6%
1 week
-2.04%
1 month
5.21%
1 year
-44.33%
YTD
-29.36%
QTD
-30.3%

Financial performance

How have Revolution Medicines's revenue and profit performed over time
Revenue
$26.84M
Gross profit
$26.84M
Operating income
-$208.56M
Net income
-$207.56M
Gross margin
100%
Net margin
-773.4%
The net margin has plunged by 156% YoY and by 21% from the previous quarter
Revolution Medicines's operating margin has plunged by 154% YoY and by 21% from the previous quarter
Revolution Medicines's net income has plunged by 65% YoY and by 11% from the previous quarter
RVMD's operating income has dropped by 64% year-on-year and by 11% since the previous quarter

Growth

What is Revolution Medicines's growth rate over time

Valuation

What is Revolution Medicines stock price valuation
P/E
N/A
P/B
2.39
P/S
49.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.94
The EPS has declined by 46% year-on-year and by 10% since the previous quarter
The P/B is 28% lower than the last 4 quarters average of 3.3
The company's equity fell by 24% YoY and by 9% QoQ
The revenue has declined by 35% year-on-year and by 9% since the previous quarter
The stock's price to sales (P/S) is 26% less than its last 4 quarters average of 65.3

Efficiency

How efficient is Revolution Medicines business performance
The return on sales has dropped by 156% year-on-year and by 22% since the previous quarter
Revolution Medicines's return on equity has decreased by 37% YoY and by 18% QoQ
RVMD's ROA is down by 37% YoY and by 16% QoQ
RVMD's ROIC is down by 22% year-on-year and by 3.1% since the previous quarter

Dividends

What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVMD.

Financial health

How did Revolution Medicines financials performed over time
Revolution Medicines's total liabilities has increased by 48% YoY but it has decreased by 2.7% from the previous quarter
Revolution Medicines's current ratio has decreased by 42% YoY and by 4.8% from the previous quarter
The debt is 88% less than the equity
The debt to equity has soared by 200% YoY and by 9% from the previous quarter
The debt has soared by 106% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.